| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Telmisartan, ramipril, or both in patients at high risk for vascular events.
|
N Engl J Med
|
2008
|
19.76
|
|
2
|
2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
|
J Hypertens
|
2013
|
18.17
|
|
3
|
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
|
Lancet
|
2011
|
13.10
|
|
4
|
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
|
Eur Heart J
|
2013
|
12.73
|
|
5
|
Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial.
|
JAMA
|
2005
|
7.35
|
|
6
|
Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.
|
Lancet
|
2004
|
5.19
|
|
7
|
Use of ramipril in preventing stroke: double blind randomised trial.
|
BMJ
|
2002
|
4.91
|
|
8
|
Urinary sodium and potassium excretion and risk of cardiovascular events.
|
JAMA
|
2011
|
4.68
|
|
9
|
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.
|
Lancet
|
2015
|
3.79
|
|
10
|
Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.
|
JAMA
|
2003
|
3.71
|
|
11
|
Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial.
|
JAMA
|
2010
|
3.34
|
|
12
|
Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials.
|
Circulation
|
2010
|
2.74
|
|
13
|
Specific barriers to the conduct of randomized trials.
|
Clin Trials
|
2008
|
2.68
|
|
14
|
2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension.
|
Blood Press
|
2013
|
2.62
|
|
15
|
Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
|
Am Heart J
|
2004
|
2.25
|
|
16
|
Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET).
|
Circulation
|
2012
|
2.25
|
|
17
|
Ambulatory blood pressure values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET).
|
Hypertension
|
2012
|
2.02
|
|
18
|
Prior blunt chest trauma may be a cause of single vessel coronary disease; hypothesis and review.
|
Int J Cardiol
|
2005
|
1.81
|
|
19
|
Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET).
|
Circulation
|
2011
|
1.77
|
|
20
|
Dynamic interactions between musical, cardiovascular, and cerebral rhythms in humans.
|
Circulation
|
2009
|
1.71
|
|
21
|
Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial.
|
J Hypertens
|
2013
|
1.62
|
|
22
|
Cognitive impairment and risk of cardiovascular events and mortality.
|
Eur Heart J
|
2012
|
1.60
|
|
23
|
The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls.
|
Eur Heart J
|
2009
|
1.52
|
|
24
|
Home telemonitoring in heart failure patients: the HHH study (Home or Hospital in Heart Failure).
|
Eur J Heart Fail
|
2009
|
1.50
|
|
25
|
Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies.
|
J Hypertens
|
2012
|
1.49
|
|
26
|
Flash pulmonary oedema and bilateral renal artery stenosis: the Pickering syndrome.
|
Eur Heart J
|
2011
|
1.45
|
|
27
|
Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis.
|
J Hypertens
|
2014
|
1.40
|
|
28
|
Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).
|
J Am Coll Cardiol
|
2012
|
1.28
|
|
29
|
Baseline Characteristics and Early Blood Pressure Control in the CONVINCE Trial.
|
Hypertension
|
2001
|
1.26
|
|
30
|
Relationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention: a prospective cohort study of 31 546 high-risk individuals from 40 countries.
|
Circulation
|
2012
|
1.24
|
|
31
|
Prognostic implications of baroreflex sensitivity in heart failure patients in the beta-blocking era.
|
J Am Coll Cardiol
|
2009
|
1.18
|
|
32
|
Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.
|
Am Heart J
|
2008
|
1.01
|
|
33
|
Home telemonitoring of vital signs and cardiorespiratory signals in heart failure patients: system architecture and feasibility of the HHH model.
|
Int J Cardiol
|
2006
|
0.95
|
|
34
|
Predictors of adverse outcome among patients with hypertension and coronary artery disease.
|
J Am Coll Cardiol
|
2006
|
0.94
|
|
35
|
Albuminuria and rapid loss of GFR and risk of new hip and pelvic fractures.
|
Clin J Am Soc Nephrol
|
2012
|
0.93
|
|
36
|
Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.
|
Circulation
|
2009
|
0.93
|
|
37
|
Clinical relevance of short-term day-time breathing disorders in chronic heart failure patients.
|
Eur J Heart Fail
|
2007
|
0.92
|
|
38
|
[Rehabilitation and models of domiciliary care of patients with chronic heart failure: preliminary results of the HHH study].
|
Monaldi Arch Chest Dis
|
2005
|
0.92
|
|
39
|
Effects of unilateral and bilateral carotid baroreflex stimulation on cardiac and neural sympathetic discharge oscillatory patterns.
|
Circulation
|
2003
|
0.88
|
|
40
|
Progress and problems for randomized clinical trials: from streptomycin to the era of megatrials.
|
Eur Heart J
|
2006
|
0.88
|
|
41
|
Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients.
|
Eur J Cardiovasc Prev Rehabil
|
2003
|
0.87
|
|
42
|
Cardiovascular protection for all individuals at high risk: evidence-based best practice.
|
Clin Res Cardiol
|
2008
|
0.86
|
|
43
|
Influenza vaccination and major adverse vascular events in high-risk patients.
|
Circulation
|
2012
|
0.86
|
|
44
|
Alcohol consumption and the risk of incident atrial fibrillation among people with cardiovascular disease.
|
CMAJ
|
2012
|
0.86
|
|
45
|
Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease.
|
Am Heart J
|
2013
|
0.84
|
|
46
|
Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?
|
Eur Heart J
|
2012
|
0.83
|
|
47
|
Impact of cigarette smoking in high-risk patients participating in a clinical trial. A substudy from the Heart Outcomes Prevention Evaluation (HOPE) trial.
|
Eur J Cardiovasc Prev Rehabil
|
2005
|
0.81
|
|
48
|
1999 WHO/ISH Hypertension Guidelines--highlights & ESH update.
|
J Hypertens
|
2002
|
0.81
|
|
49
|
The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
|
Eur J Prev Cardiol
|
2013
|
0.81
|
|
50
|
Effect of long-term therapy with ramipril in high-risk women.
|
J Am Coll Cardiol
|
2002
|
0.80
|
|
51
|
Global differences in blood pressure control and clinical outcomes in the INternational VErapamil SR-Trandolapril STudy (INVEST).
|
Clin Cardiol
|
2005
|
0.80
|
|
52
|
Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical region.
|
J Hypertens
|
2005
|
0.80
|
|
53
|
Clinical and haemodynamic correlates of heart rate turbulence as a non-invasive index of baroreflex sensitivity in chronic heart failure.
|
Clin Sci (Lond)
|
2011
|
0.80
|
|
54
|
Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET/TRANSCEND research programme.
|
Diabetes Res Clin Pract
|
2009
|
0.80
|
|
55
|
Frequency-dependent baroreflex control of blood pressure and heart rate during physical exercise.
|
Int J Cardiol
|
2005
|
0.79
|
|
56
|
Pathophysiological and clinical relevance of simplified monitoring of nocturnal breathing disorders in heart failure patients.
|
Eur J Heart Fail
|
2009
|
0.78
|
|
57
|
New methods for risk stratification in patients after myocardial infarction autonomic control and substrate sensitivity.
|
J Am Coll Cardiol
|
2007
|
0.78
|
|
58
|
Hypertrophy at ECG and its regression during treatment survey (HEART survey). Rationale, design and baseline characteristics of patients.
|
Ital Heart J
|
2003
|
0.77
|
|
59
|
Nonpharmacological treatments for hypertension.
|
J Hypertens
|
2012
|
0.75
|
|
60
|
Who is fooling us?
|
Lancet
|
2002
|
0.75
|
|
61
|
Blood pressure levels for treatment of uncomplicated diabetes in primary care.
|
J Hypertens
|
2013
|
0.75
|
|
62
|
Enoxaparin versus unfractionated heparin in ST-elevation myocardial infarction.
|
N Engl J Med
|
2006
|
0.75
|
|
63
|
Preventing stroke with ramipril--authors' reply.
|
BMJ
|
2003
|
0.75
|
|
64
|
1999 WHO/ISH Hypertension Guidelines--highlights & ESH Update.
|
Blood Press
|
2003
|
0.75
|
|
65
|
Pioneers in cardiology: Peter Sleight, FRCP, MD. Interview by Jennifer Taylor.
|
Circulation
|
2007
|
0.75
|
|
66
|
Music and the heart.
|
Eur Heart J
|
2015
|
0.75
|
|
67
|
Cardiovascular variability is/is not an index of autonomic control of circulation.
|
J Appl Physiol (1985)
|
2006
|
0.75
|
|
68
|
The Oxford years--the last of the Quarto!
|
Cardiovasc Res
|
2007
|
0.75
|
|
69
|
Heart rate and blood pressure interactions in the development of erectile dysfunction in high-risk cardiovascular patients.
|
Eur J Prev Cardiol
|
2013
|
0.75
|
|
70
|
We could all learn from the Italian cardiologists.
|
Am Heart J
|
2004
|
0.75
|
|
71
|
Music and the heart.
|
Eur Heart J
|
2015
|
0.75
|